GeoVax Reports Progress on AIDS Vaccine

GeoVax Labs is beginning a Phase II clinical trial evaluating its AIDS vaccine.

Previous Phase I data showed that the vaccine produced anti-HIV T-cells. The upcoming Phase II study will further evaluate the vaccine’s safety and immunogenicity in 225 healthy volunteers from the U.S. and South America, GeoVax said.

The trial will be conducted by the HIV Vaccine Trials Network, which is supported by the NIH. Subject to FDA approval, it will begin early this fall.